Cell Source Financials
| CLCS Stock | USD 0.50 0.02 4.17% |
With this module, you can analyze Cell financials for your investing period. You should be able to track the changes in Cell Source individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
Cell |
Understanding current and past Cell Source Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Cell Source's financial statements are interrelated, with each one affecting the others. For example, an increase in Cell Source's assets may result in an increase in income on the income statement.
The data published in Cell Source's official financial statements typically reflect Cell Source's business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Cell Source's quantitative information. For example, before you start analyzing numbers published by Cell accountants, it's essential to understand Cell Source's liquidity, profitability, and earnings quality within the context of the Healthcare space in which it operates.
Please note, the imprecision that can be found in Cell Source's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Cell Source. Check Cell Source's Beneish M Score to see the likelihood of Cell Source's management manipulating its earnings.
Cell Source Stock Summary
Cell Source competes with Opthea, Molecular Partners, Edgewise Therapeutics, Iteos Therapeutics, and Antibe Therapeutics. Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance. Cell Source, Inc. was founded in 2012 and is headquartered in New York, New York. Cell Source operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 1 people.| Instrument | USA OTC Stock View All |
| Exchange | OTCQB Exchange |
| ISIN | US15114L1044 |
| Business Address | 57 West 57th |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.cell-source.com |
| Phone | 646 416 7896 |
| Currency | USD - US Dollar |
Cell Source Key Financial Ratios
There are many critical financial ratios that Cell Source's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Cell Source reports annually and quarterly.| Return On Asset | -3.78 | |||
| Beta | -64.41 |
Cell Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Cell Source's current stock value. Our valuation model uses many indicators to compare Cell Source value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cell Source competition to find correlations between indicators driving Cell Source's intrinsic value. More Info.Cell Source is number one stock in return on asset category among its peers. It also is the top company in current valuation category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cell Source's earnings, one of the primary drivers of an investment's value.Cell Source Systematic Risk
Cell Source's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Cell Source volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Cell Source correlated with the market. If Beta is less than 0 Cell Source generally moves in the opposite direction as compared to the market. If Cell Source Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Cell Source is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Cell Source is generally in the same direction as the market. If Beta > 1 Cell Source moves generally in the same direction as, but more than the movement of the benchmark.
Cell Source December 22, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Cell Source help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Cell Source. We use our internally-developed statistical techniques to arrive at the intrinsic value of Cell Source based on widely used predictive technical indicators. In general, we focus on analyzing Cell OTC Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Cell Source's daily price indicators and compare them against related drivers.
| Downside Deviation | 15.55 | |||
| Information Ratio | 0.0924 | |||
| Maximum Drawdown | 92.05 | |||
| Value At Risk | (22.73) | |||
| Potential Upside | 45.24 |
Additional Tools for Cell OTC Stock Analysis
When running Cell Source's price analysis, check to measure Cell Source's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cell Source is operating at the current time. Most of Cell Source's value examination focuses on studying past and present price action to predict the probability of Cell Source's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cell Source's price. Additionally, you may evaluate how the addition of Cell Source to your portfolios can decrease your overall portfolio volatility.